biohack.The longevity wire
LIVE WIREUpdated · scanning every 6 hours
23:41 Melanoma cell therapy controlled by an approved drug enrolls new groups✦23:41 ADHD drugs may ease perimenopause brain fog, early review suggests✦23:36 $1.55 billion pill for rare muscle disease failed big trial, maker says✦17:44 Lab study points to a protein that may help drive aging in testicles✦17:43 Trial will test whether stool-transplant capsules slow aging in 68 adults✦17:39 Novartis pill cut MS relapses more than an older drug in two big trials✦11:36 Women on menopause hormones lost a bit more weight on Ozempic-style drugs✦05:37 Sugar found mostly in red meat tied to higher diabetes risk in early study✦23:41 Melanoma cell therapy controlled by an approved drug enrolls new groups✦23:41 ADHD drugs may ease perimenopause brain fog, early review suggests✦23:36 $1.55 billion pill for rare muscle disease failed big trial, maker says✦17:44 Lab study points to a protein that may help drive aging in testicles✦17:43 Trial will test whether stool-transplant capsules slow aging in 68 adults✦17:39 Novartis pill cut MS relapses more than an older drug in two big trials✦11:36 Women on menopause hormones lost a bit more weight on Ozempic-style drugs✦05:37 Sugar found mostly in red meat tied to higher diabetes risk in early study
← All story threadsSTORY THREAD

Pill for Becker muscular dystrophy.

1 report so far. New developments are added to this thread as they happen.

  1. Nov 3, 2026
    FAILS ITS FIRST BIG TRIAL AFTER $1.55B PURCHASECompany results · 175 adults

    $1.55 billion pill for rare muscle disease failed big trial, maker says

    Servier says sevasemten, a pill it bought from Edgewise for $1.55 billion, did not slow Becker muscular dystrophy in an 18-month trial against a dummy pill.